Pharma major Lupin launches injection to cure thiamine deficiency in US

Pharmaceutical company Lupin on Monday announced that it has launched its generic Thiamine Hydrochloride injection 200 mg/2 mL (100 mg/mL) multiple-dose vials used for treatment of thiamine deficiency in the US. The launch follows alliance partner Caplin Steriles receiving an approval for its ANDA (Abbreviated New Drug Application) from the US Food and Drug Administration (USFDA).

The injection is therapeutically equivalent to the reference listed drug Thiamine Hydrochloride Injection 200 mg/2 ml (100mg/mL) of Fresenius Kabi USA LLC.

Thiamine Hydrochloride injection had estimated annual sales of USD 35 million in the US, Lupin said citing IQVIA MAT April 2023 data.


Inputs from PTI